PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

In chronic lymphocytic leukemia (CLL), mutation and loss of p53 and ATM abrogate DNA damage signalling and predict poorer response and shorter survival. We hypothesised that poly (ADP-ribose) polymerase (PARP) activity, which is crucial for repair of DNA breaks induced by oxidative stress or chemoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Principais autores: Herriott, Ashleigh, Tudhope, Susan J., Junge, Gesa, Rodrigues, Natalie, Patterson, Miranda J., Woodhouse, Laura, Lunec, John, Hunter, Jill E., Mulligan, Evan A., Cole, Michael, Allinson, Lisa M., Wallis, Jonathan P., Marshall, Scott, Wang, Evelyn, Curtin, Nicola J., Willmore, Elaine
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791280/
https://ncbi.nlm.nih.gov/pubmed/26539646
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados